Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study.

J Immunother Cancer · 2025 · PMC12506459 · PMID 41052885

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Increases in IFNγ and CXCL9 were observed after the first administration of nivolumab SC with or without HuPH20, with a strong trend of cycle-day effects but no apparent dose-dependence ( figure 4B,C ) in the serum across all tumor types.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.